Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV-infection prior to study enrollment~* Screening laboratory result indicating HCV genotype 2 infection~* Subject has plasma HCV ribonucleic acid (RNA) level greater than 10,000 IU/mL at Screening~* Voluntarily sign an informed consent~Exclusion Criteria:~* Co-infection of Hepatitis B Virus (HBV), human immunodeficiency virus (HIV) and any HCV genotype other than genotype 2~* Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir, simeprevir and boceprevir~* Any cause of liver disease other than chronic HCV-infection, including but not limited to the following: hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease; autoimmune hepatitis; alcoholic liver disease; drug-related liver disease~* Clinically significant laboratory abnormalities~* Uncontrolled clinically significant disease, disorder or medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 plus RBV for 12 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
- ABT-450/r/ABT-267 plus RBV for 16 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).